"News is MIA, but the charts are whispering drama! 📉 The stock got rejected at $245 (hello, resistance!) and RSI is stuck in no-man's-land (47 = yawn). Volume spiked on the drop—big players might be bailing. 9-day WMA just crossed *under* the 21-day... not a love story. Until news gives this pup a bone, it's a SELL or at least a 'don't catch this falling knife.' #BearishBrewing ☕"  

*(P.S. If news drops bullish later, we pivot—but techs say fade the rally for now.)*

Insider buying is a quiet but powerful vote of confidence. 🧐 While the chart's story is missing its pages (no technicals to read), two separate insiders putting their own cash on the line isn't a coincidence. It's a bullish whisper from those who know the company best. When the suits are buying, I'm leaning BUY. #FollowTheSmartMoney

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CSL Limited CSL.AX: 141.04 AUD

Bullish views

Bearish views